Royalty Pharma plc

A tough capital market for biotechs may be increasingly driving companies to ink royalty deals, but the growing popularity of the alternative funding route also has to do with better pricing and more

Teva Pharmaceutical Industries – best known as a generic drug leader – has been focused on building an innovative drug portfolio, a key pillar of CEO Richard Francis’s “pivot to growth” strategy. The

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

Royalty Pharma has built a unique and valuable business model within the biopharma sector, buying royalty revenue streams in exchange for capital to finance drug development and commercialization. And